Cargando…

Health impacts of COVID-19 disruptions to primary cervical screening by time since last screen: A model-based analysis for current and future disruptions

BACKGROUND. We evaluated how temporary disruptions to primary cervical cancer (CC) screening services may differentially impact women due to heterogeneity in their screening history and test modality. METHODS. We used three CC models to project the short- and long-term health impacts assuming an und...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burger, Emily A., de Kok, Inge M.C.M., O’Mahony, James F, Rebolj, Matejka, Jansen, Erik E.L., de Bondt, Daniel D., Killen, James, Hanley, Sharon J., Castanon, Alejandra, Kim, Jane J., Canfell, Karen, Smith, Megan A., Regan, Mary Caroline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9347288/ https://www.ncbi.nlm.nih.gov/pubmed/35923317 http://dx.doi.org/10.1101/2022.07.25.22278011

Ejemplares similares

A model-based analysis of the health impacts of COVID-19 disruptions to primary cervical screening by time since last screen for current and future disruptions
por: Burger, Emily A, et al.
Publicado: (2022)

Impact of disruptions and recovery for established cervical screening programs across a range of high-income country program designs, using COVID-19 as an example: A modelled analysis
por: Smith, Megan A., et al.
Publicado: (2021)

COVID-19 disruption to cervical cancer screening in England
por: Castanon, Alejandra, et al.
Publicado: (2022)

Cervical screening during the COVID-19 pandemic: optimising recovery strategies
por: Castanon, Alejandra, et al.
Publicado: (2021)

Recovery strategies following COVID-19 disruption to cervical cancer screening and their impact on excess diagnoses
por: Castanon, Alejandra, et al.
Publicado: (2021)

Is a delay in the introduction of human papillomavirus-based cervical screening affordable?
por: Castañon, Alejandra, et al.
Publicado: (2018)

Human Papillomavirus Testing in the Last Cervical Screening Round at Age 60–64 Years
por: Schroll, Jeppe Bennekou, et al.
Publicado: (2021)

Effects of cancer screening restart strategies after COVID-19 disruption
por: Kregting, Lindy M., et al.
Publicado: (2021)

A modelled analysis of the impact of COVID-19-related disruptions to HPV vaccination
por: Velentzis, Louiza S, et al.
Publicado: (2023)

Correction: Effects of cancer screening restart strategies after COVID-19 disruption
por: Kregting, Lindy M., et al.
Publicado: (2021)

Cytology interpretation after a change to HPV testing in primary cervical screening: Observational study from the English pilot
por: Rebolj, Matejka, et al.
Publicado: (2022)

Effects of cancer screening restart strategies after COVID-19 disruption
por: Kregting, L., et al.
Publicado: (2020)

The Impact of Different Screening Model Structures on Cervical Cancer Incidence and Mortality Predictions: The Maximum Clinical Incidence Reduction (MCLIR) Methodology
por: de Kok, Inge M. C. M., et al.
Publicado: (2020)

The impact of catch-up bivalent human papillomavirus vaccination on cervical screening outcomes: an observational study from the English HPV primary screening pilot
por: Rebolj, Matejka, et al.
Publicado: (2022)

Concurrent participation in breast, cervical, and colorectal cancer screening programmes in Denmark: A nationwide registry-based study
por: Njor, Sisse Helle, et al.
Publicado: (2023)

Human papillomavirus testing in primary cervical screening and the cut-off level for hybrid capture 2 tests: systematic review
por: Rebolj, Matejka, et al.
Publicado: (2011)

Risk Stratification in Cost-Effectiveness Analyses of Cancer Screening: Intervention Eligibility, Strategy Choice, and Optimality
por: O’Mahony, James F.
Publicado: (2021)

Human Papillomavirus Assays and Cytology in Primary Cervical Screening of Women Aged 30 Years and Above
por: Rebolj, Matejka, et al.
Publicado: (2016)

The impact of healthcare costs in the last year of life and in all life years gained on the cost-effectiveness of cancer screening
por: de Kok, I M C M, et al.
Publicado: (2009)

Disagreement between Human Papillomavirus Assays: An Unexpected Challenge for the Choice of an Assay in Primary Cervical Screening
por: Rebolj, Matejka, et al.
Publicado: (2014)

Interpreting cost-effectiveness ratios in a cost-effectiveness analysis of risk-tailored prostate screening: A critique of Callender et al.
por: O'Mahony, James F.
Publicado: (2020)

Cost-effectiveness of population-based screening for colorectal cancer
por: O'Mahony, J F
Publicado: (2013)

Potential global loss of life expected due to COVID-19 disruptions to organised colorectal cancer screening
por: Worthington, Joachim, et al.
Publicado: (2023)

A Systematic Review of Cost-Effectiveness Analyses of Colorectal Cancer Screening in Europe: Have Studies Included Optimal Screening Intensities?
por: Pokharel, Rajani, et al.
Publicado: (2023)

Adherence to follow‐up after the exit cervical cancer screening test at age 60–64: A nationwide register‐based study
por: Jørgensen, Susanne F., et al.
Publicado: (2021)

Cervical cancer incidence after normal cytological sample in routine screening using SurePath, ThinPrep, and conventional cytology: population based study
por: Rozemeijer, Kirsten, et al.
Publicado: (2017)

Landscape of enhancer disruption and functional screen in melanoma cells
por: Wang, Zhao, et al.
Publicado: (2023)

HPV prevalence and genotype distribution in a population-based split-sample study of well-screened women using CLART HPV2 Human Papillomavirus genotype microarray system
por: Bonde, Jesper, et al.
Publicado: (2014)

A disruptive sequencer meets disruptive publishing
por: Loman, Nick, et al.
Publicado: (2015)

Small-molecule compound from AlphaScreen disrupts tau-glycan interface
por: Faris, Shannon, et al.
Publicado: (2022)

Modelling the impact of the coronavirus pandemic on bowel cancer screening outcomes in England: A decision analysis to prepare for future screening disruption
por: Mandrik, Olena, et al.
Publicado: (2022)

783 IMPACT OF COVID-19 RELATED DISRUPTIONS TO COLORECTAL CANCER SCREENING PROGRAMS IN THREE COUNTRIES: A COMPARATIVE MODELLING STUDY
por: De Jonge, Lucie, et al.
Publicado: (2021)

A Simple Cost-Effectiveness Model of Screening: An Open-Source Teaching and Research Tool Coded in R
por: Lin, Yi-Shu, et al.
Publicado: (2023)

In Vitro Reporter Assays for Screening of Chemicals That Disrupt Androgen Signaling
por: Bagchi Bhattacharjee, Gargi, et al.
Publicado: (2014)

Cells to Systems Screening for Thyroid Hormone Disrupting Chemicals in the Brain
por: Furlow, J David, et al.
Publicado: (2021)

COVID-related disruption in mammographic screening: a year later
por: Toss, A., et al.
Publicado: (2022)

Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis
por: Kim, Jane J., et al.
Publicado: (2021)

Assessing last-mile distribution resilience under demand disruptions
por: Pahwa, Anmol, et al.
Publicado: (2023)

Investigating the decrease in participation in the Dutch cervical cancer screening programme: The role of personal and organisational characteristics
por: Aitken, Clare A., et al.
Publicado: (2021)

Shift in harms and benefits of cervical cancer screening in the era of HPV screening and vaccination: a modelling study
por: Kaljouw, Sylvia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4r6ntm073is98uf82g0qjejr1a